U.S. Markets closed

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.5786-0.04 (-5.93%)
At close: 4:11PM EDT
People also watch

Ampio Pharmaceuticals, Inc.

373 Inverness Parkway
Suite 200
Englewood, CO 80112
United States

Full Time Employees21

Key Executives

Mr. Michael MacalusoFounder, Chairman and Chief Exec. Officer305kN/A65
Dr. David Bar-Or M.D.Chief Scientific Officer and Director305kN/A68
Mr. Philip H. CoelhoDirector89kN/A73
Mr. Thomas E Chilcott IIIInterim Chief Financial Officer & ControllerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Corporate Governance

Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.